thermozymocidin and Candidiasis

thermozymocidin has been researched along with Candidiasis* in 2 studies

Other Studies

2 other study(ies) available for thermozymocidin and Candidiasis

ArticleYear
Sphingolipidomics of drug resistant Candida auris clinical isolates reveal distinct sphingolipid species signatures.
    Biochimica et biophysica acta. Molecular and cell biology of lipids, 2021, Volume: 1866, Issue:1

    Independent studies from our group and others have provided evidence that sphingolipids (SLs) influence the antimycotic susceptibility of Candida species. We analyzed the molecular SL signatures of drug-resistant clinical isolates of Candida auris, which have emerged as a global threat over the last decade. This included Indian hospital isolates of C. auris, which were either resistant to fluconazole (FLC

    Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Chromatography, Liquid; Depsipeptides; Drug Resistance, Multiple, Fungal; Fatty Acids, Monounsaturated; Fluconazole; Glucosylceramides; Humans; Lipidomics; Tandem Mass Spectrometry

2021
Myriocin significantly increases the mortality of a non-mammalian model host during Candida pathogenesis.
    PloS one, 2013, Volume: 8, Issue:11

    Candida albicans is a major human pathogen whose treatment is challenging due to antifungal drug toxicity, drug resistance and paucity of antifungal agents available. Myrocin (MYR) inhibits sphingosine synthesis, a precursor of sphingolipids, an important cell membrane and signaling molecule component. MYR also has dual immune suppressive and antifungal properties, potentially modulating mammalian immunity and simultaneously reducing fungal infection risk. Wax moth (Galleria mellonella) larvae, alternatives to mice, were used to establish if MYR suppressed insect immunity and increased survival of C. albicans-infected insects. MYR effects were studied in vivo and in vitro, and compared alone and combined with those of approved antifungal drugs, fluconazole (FLC) and amphotericin B (AMPH). Insect immune defenses failed to inhibit C. albicans with high mortalities. In insects pretreated with the drug followed by C. albicans inoculation, MYR+C. albicans significantly increased mortality to 93% from 67% with C. albicans alone 48 h post-infection whilst AMPH+C. albicans and FLC+C. albicans only showed 26% and 0% mortalities, respectively. MYR combinations with other antifungal drugs in vivo also enhanced larval mortalities, contrasting the synergistic antifungal effect of the MYR+AMPH combination in vitro. MYR treatment influenced immunity and stress management gene expression during C. albicans pathogenesis, modulating transcripts putatively associated with signal transduction/regulation of cytokines, I-kappaB kinase/NF-kappaB cascade, G-protein coupled receptor and inflammation. In contrast, all stress management gene expression was down-regulated in FLC and AMPH pretreated C. albicans-infected insects. Results are discussed with their implications for clinical use of MYR to treat sphingolipid-associated disorders.

    Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Fatty Acids, Monounsaturated; Humans; Larva; Mice; Moths

2013